Skip to main content
OpenTrials
Completed

NCT Number: NCT01835652

The Effects of Exercise in Parkinson's Disease

Parkinson's disease is caused by a reduction of dopamine causing motor deficits. The investigators are studying how exercise can help PD patients by increasing dopamine release in an area of the brain that coordinates movement, the striatum. The investigators will enroll PD patients into two groups; one group will complete a 12-week aerobic exercise program and the other will complete a 12-week control program including yoga and stretching only. The investigators will measure changes in dopamine release before and after either 12-week intervention. Subjects will complete motor and cognitive questionnaires in addition to functional magnetic resonance imaging and positron emission tomography neuroimaging.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pacific Parkinson's Research Centre

Vancouver, British Columbia, V6T 2B5, Canada

About this study

The purpose of this study is to determine the basis for symptomatic and disease modifying benefits of exercise in Parkinson's disease (PD).

Although the benefits of exercise in PD have been purported for several decades, only recently have there been controlled reports of symptomatic benefits in Parkinson's disease in terms of bradykinesia, postural balance and quality of life. There have been unsubstantiated suggestions that exercise may improve cognition and mood in PD.

The mechanisms underlying such benefits are poorly understood. Exercise may induce dopamine release, thereby contributing to improved motor function in the dorsal striatum, and to enhanced mood and reduced apathy in the ventral striatum.

We will test the hypotheses that exercise results in altered synaptic plasticity in the form of altered connectivity in response to aerobic exercise and reward-induced dopamine release. We will assess networks of functional connectivity using functional magnetic resonance imaging and measure dopamine release with positron emission tomography (PET).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Idiopathic PD according to UK Brain Bank criteria (modified to permit inclusion of subjects with a family history)
  • Ages 40-70
  • Mild to moderate Parkinsonism (Hoehn & Yahr stages I-III)

Exclusion criteria

General exclusion criteria will include:

  • more than 120 minutes per week of activities >3 MET or a score exceeding 4 on the "Baseline Exercise Screening Tool" (Appendix, Fig. 1);
  • atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);
  • significant osteoporosis or arthritis;
  • other neurological disease (e.g. myopathy);
  • self-reports claustrophobia;
  • history of cancer within 5 years of study participation;
  • high dose of radiation from other procedures within the year;
  • taking rasagiline or selegiline for PD therapy;
  • diabetic;
  • not able to tolerate being off PD medication for up to 24 hours;
  • BMI of 35 or more; and
  • a female subject who is breast-feeding or pregnant.

Exclusion criteria

for MRI scanning and magnetic stimulation from rTMS scanning includes:

  • artificial heart valve;
  • brain aneurysm clip;
  • electrical stimulator for nerves or bones;
  • ear or eye implant;
  • implanted drug infusion pump;
  • coil, catheter, or filter in any blood vessel;
  • orthopedic hardware (artificial joint, plate, screws);
  • other metallic prostheses;
  • shrapnel, bullets, or other metal fragments;
  • surgery or tattoos (including tattooed eyeliner) in the last six weeks;
  • have a cardiac pacemaker, wires or defibrillator;
  • have had an injury where a piece of metal lodged in your eye or orbit;
  • have a ferromagnetic aneurysm clip; and
  • have a history of seizures.

Subjects may be excluded following study enrollment if they meet any of the following exclusion criteria:

  • significant cognitive impairment (Montreal Cognitive Assessment score < 24) or depression (Beck Depression Inventory score > 18);
  • significant or unstable cardiovascular or respiratory disease - all subjects will undergo a screening exercise bicycle stress test; or
  • failure to comply with the exercise or yoga/stretching intervention program, including missing 5 sessions or missing three sessions in a row.

Treatment and study plan

Active Exercise

Other

Passive Exercise

Other

Primary outcomes

  1. PET

    Time frame: 3 months

    Dopamine release will be assessed using positron emission tomography (PET)

Secondary outcomes

  1. fMRI

    Time frame: 3 months

    fMRI will be performed to record response to rewarding stimuli

Other outcomes

  1. Clinical Measures

    Time frame: 3 months

    Motor function will be assessed using the MDS-Unified Parkinson's Disease Rating Scale, finger tapping and Purdue Pegboard. Cognitive function will be assessed using the Montreal Cognitive Assessment, Wisconsin Card-Sorting Task, Trail-Making B Test and a computerized reaction time test. Mood and apathy will be assessed using the Beck Depression Inventory and Starkstein Apathy Scale.

Sponsors and collaborators

Lead sponsor

Pacific Parkinson's Research Centre

Other

Registry information

Official study title

The Effects of Exercise in Parkinson's Disease.

Acronym: PET

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Apr 19, 2013
Registry last updated
Mar 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.